Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
Eleonora Vianello, Patrícia Gonzalez‐Dias, Suzanne van Veen, Carmen G Engele, Edwin Quinten, Thomas P. Monath, Donata Medaglini, Selidij T Agnandij, Rafi Ahmed, Jenna Anderson, Floriane Auderset, Philip Bejon, Luisa Borgianni, Jessica S. Brosnahan, Annalisa Ciabattini, Olivier Engler, Mariëlle C. Haks, Ali M Harandi, Donald Gray Heppner, Alice Gerlini, Angela Huttner, Peter G Kremsner, Donata Medaglini, Thomas P. Monath, Francis M Ndungu, Patricia Njuguna, Tom H M Ottenhoff, David Pejoski, Mark Page, Gianni Pozzi, Francesco Santoro, Claire‐Anne Siegrist, Selidij T Agnandij, Luisa Borgianni, Annalisa Ciabattini, Sheri Dubey, M.J. Eichberg, Olivier Engler, Essone P Ndong, Ali M Harandi, Alice Gerlini, Angela Huttner, Peter G Kremsner, Lumeka Kabwende, Donata Medaglini, Helder I. Nakaya, Patricia G. Carvalho, Tom H M Ottenhoff, Gianni Pozzi, Sylvia Rothenberger, Francesco Santoro, Claire‐Anne Siegrist, Eleonora Vianello, Sravya Sowdamini Nakka, Mariëlle C. Haks, Suzanne van Veen, Francesco Santoro, Angela Huttner, Sheri Dubey, M.J. Eichberg, Francis M Ndungu, Peter G. Kremsner, Paulin N. Essone, Sélidji Todagbé Agnandji, Claire‐Anne Siegrist, Helder I. Nakaya, Tom H M Ottenhoff, Mariëlle C. Haks
Abstract
BACKGROUND: A recombinant vesicular stomatitis virus vector expressing the Zaire Ebola virus glycoprotein (rVSVΔG-ZEBOV-GP) vaccine has been reported as safe, immunogenic, and highly protective in a ring vaccination trial. We aimed to identify transcriptomic immune response biomarker signatures induced by vaccination and associated signatures with its immunogenicity and reactogenicity to better understand the potential mechanisms of action of the vaccine. METHODS: plaque-forming units [pfu]). Longitudinal transcriptomic responses (days 0, 1, 2, 3, 7, 14, and 28) were measured in whole blood using a targeted gene expression profiling platform (dual-colour reverse-transcriptase multiplex ligation-dependent probe amplification) focusing on 144 immune-related genes. The effect of time and dose on transcriptomic response was also assessed. Logistic regression with lasso regularisation was applied to identify host signatures with optimal discriminatory capability of vaccination at day 1 or day 7 versus baseline, whereas random-effects models and recursive feature elimination combined with regularised logistic regression were used to associate signatures with immunogenicity and reactogenicity. FINDINGS: pfu) of rVSVΔG-ZEBOV-GP exhibiting the largest amplitude. The most differentially expressed genes that were significantly upregulated following vaccination consisted of type I and II interferon-related genes and myeloid cell-associated markers, whereas T cell, natural killer cell, and cytotoxicity-associated genes were downregulated. A gene signature associated with immunogenicity (common to all four cohorts) was identified correlating gene expression profiles with ZEBOV-GP antibody titres and a gene signatures associated with reactogenicity (Geneva cohort) was identified correlating gene expression profiles with an adverse event (ie, arthritis). INTERPRETATION: Collectively, our results identify and cross-validate immune-related transcriptomic signatures induced by rVSVΔG-ZEBOV-GP vaccination in four cohorts of adult participants from different genetic and geographical backgrounds. These signatures will aid in the rational development, testing, and evaluation of novel vaccines and will allow evaluation of the effect of host factors such as age, co-infection, and comorbidity on responses to vaccines. FUNDING: Innovative Medicines Initiative 2 Joint Undertaking.